Regencell Bioscience (NASDAQ:RGC) Sets New 52-Week Low – Here’s Why

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $5.60 and last traded at $5.61, with a volume of 565872 shares traded. The stock had previously closed at $6.37.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Regencell Bioscience Price Performance

The firm has a 50-day moving average price of $19.56 and a two-hundred day moving average price of $25.00.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Trading of Regencell Bioscience

Several institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP acquired a new stake in Regencell Bioscience during the fourth quarter valued at approximately $92,000. Amundi acquired a new position in Regencell Bioscience during the first quarter worth $219,000. Vident Advisory LLC lifted its holdings in Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in shares of Regencell Bioscience in the 4th quarter worth approximately $275,000. Finally, Bank of America Corp DE boosted its stake in Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares in the last quarter. 0.13% of the stock is currently owned by institutional investors and hedge funds.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.